ES2491743T3 - Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso - Google Patents

Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso Download PDF

Info

Publication number
ES2491743T3
ES2491743T3 ES12151520.9T ES12151520T ES2491743T3 ES 2491743 T3 ES2491743 T3 ES 2491743T3 ES 12151520 T ES12151520 T ES 12151520T ES 2491743 T3 ES2491743 T3 ES 2491743T3
Authority
ES
Spain
Prior art keywords
conjugates
fluorescence microscopy
haptens
haptenos
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12151520.9T
Other languages
English (en)
Inventor
Jerry W. Kosmeder
Mark Lefever
Donald Johnson
Michael Farrell
Zhanna Zhilina
Christopher Bieniarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Application granted granted Critical
Publication of ES2491743T3 publication Critical patent/ES2491743T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/76—Sulfur atoms attached to a second hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un anticuerpo anti-hapteno que se une específicamente a un hapteno que es un nitroarilo, que puede ser un mono- o dinitro pirazol

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73
Recientemente se han desarrollado Citrina y Venus, dos versiones brillantes de un mutante de la GFP que emite luz amarilla (YFP) que maduran eficazmente.
Dos variedades recientemente desarrolladas de DsRed, conocidas como T1 y E57, despliegan una maduración
mejorada, lo que hace que resulten preferibles para su uso en experimentos a dos colores.
5 La fluorescencia de algunas variantes de GFP puede ser "fotoactivada" mediante una iluminación específica, que ofrece la ventaja de que la fluorescencia se puede activar en un punto temporal seleccionado. Se han desarrollado tres proteínas fluorescentes que se someten a modificación fotoquímica en el cromóforo o cerca de este, PA-GFP, Kaede y KFP1, que permiten la activación selectiva de señales de fluorescencia tras una iluminación específica y que se pueden utilizar para marcar por fluorescencia células, organelos o proteínas individuales.
10 La Tabla 1 proporciona otros ejemplos de fracciones generadoras de señales y conjugados que comprenden estas fracciones.
Tabla 1
Ejemplos de conjugados de etiqueta detectable de anticuerpo
15
Etiqueta de conjugado de anticuerpo
Recomendado para Color emitido Excitación de etiqueta Emisión de etiqueta
Lake Placid Blue (EviTag™ Quantum Dot)
Citometría de flujo, inmunoblots y microscopía de fluorescencia <450 490
Fluoresceína (es decir, FITC)
Citometría de flujo, incl. sistemas BD FAC y Guava System, y microscopía de fluorescencia 494 518
Adirondack Green (EviTag™ Quantum Dot)
Citometría de flujo, inmunoblots y microscopía de fluorescencia <450 520
Rhodamine Green
Microscopía de fluorescencia 502 527
Catskill Green (EviTag™ Quantum Dot)
Microscopía de fluorescencia <450 540
Rodamina 6G
Citometría de flujo, inmunoblots y microscopía de fluorescencia 525 555
Hops Yellow (EviTag™ Quantum Dot)
Citometría de flujo, inmunoblots y microscopía de fluorescencia <450 560
Amersham Cy3
Microscopía de fluorescencia 550 565
R-Phycoerythrin (PE)
Citometría de flujo, sistemas Luminex® y Guava, ensayos de FRET, electroforesis capilar y uso (495)565 575
75
con FITC para doble etiquetado
Rhodamine Red
Citometría de flujo, microscopía de fluorescencia 560 580
Birch Yellow (EviTag™ Quantum Dot)
Microscopía de fluorescencia <450 580
Amersham Cy3.5
Microscopía de fluorescencia 581 596
Fort Orange (EviTag™ Quantum Dot)
Citometría de flujo, inmunoblots y microscopía de fluorescencia <450 600
SulfoRhodamine (Alias Texas Red®)
Citometría de flujo y microscopía de fluorescencia 596 615
Amersham Cy5
Immunoblot, incl. Amersham Typhoon System, y aplicaciones inmunofluorescentes 650 670
Allophycocyanin (APC)
Ensayos FRET y ensayos HTRF 652 670
Amershani Cy5.5
Immunoblot, especialmente sistemas LI-COR Odyssey 675 694
Biotina
Citometría de flujo y otras aplicaciones fluorescentes -
Muchas de estas etiquetas se pueden utilizar con múltiples anticuerpos que no interreaccionan para crear ensayos multiplexados personalizados.
VII. Procesos para la formación de conjugados de hapteno -Esquemas de reacción
5 Los siguientes esquemas proporcionan ejemplos de realizaciones de un método útil para producir conjugados de la presente realización. Otras metodologías sintéticas también resultan útiles para producir estos conjugados y no se deberá interpretar que los esquemas siguientes limitan el método a las metodologías sintéticas concretas ilustradas.
1. Conjugados de nitropirazol
El Esquema 1 ilustra un método adecuado para acoplar ejemplos de haptenos de nitropirazol a un conector de óxido 10 de alquileno y posteriormente a un vehículo de proteína.
76
imagen74
imagen75
imagen76
imagen77
imagen78
imagen79
imagen80
imagen81
imagen82
imagen83
imagen84
imagen85
imagen86
imagen87
imagen88
imagen89
imagen90
imagen91
imagen92
imagen93
imagen94
imagen95
imagen96
imagen97
imagen98
imagen99
imagen100
imagen101
imagen102
imagen103
imagen104
imagen105
imagen106
imagen107
imagen108
imagen109
imagen110
imagen111
imagen112
imagen113
imagen114
imagen115
imagen116
imagen117
imagen118
tampón de fosfatos (PBS) 0,15 molar. La concentración de BSA-dPEG8-benzofurazano fue de 2 µg/ml, y la concentración por pocillo de 50 µL. Estas muestras se incubaron a 4 ˚C hasta el día siguiente. Se utilizó leche en polvo desnatada (NFDM) al 1% (10 mg/mL, 300 µL/por pocillo) como reactivo de bloqueo, seguido de incubación a 37 ˚C durante 120 minutos. Las placas se lavaron, cuando se consideró necesario, utilizando 0,15 M PBS que
5 contenía un 0,05% de Tween 20. A continuación se utilizó cada hapteno testado para producir antisuero de ratón. Se utilizó una concentración total de 80 [micro]l por pocillo de antisuero de ratón diluido con un 1% de NFDM en 0,15 M PBAS, utilizando el protocolo de diluciones y de diseño de placas que se indica más adelante en la Tabla 6. Las placas se incubaron a continuación a 37 ˚C durante 150 minutos. Se utilizó un conjugado de peroxidasa de rábanoanticuerpo de cabra anti-ratón (Gt-α-Mu-HRP, Pierce) como anticuerpo secundario a una concentración de 1:10,000
10 en 0.15 M PBS con un 0,05% de Tween 20 para obtener un volumen total de 50 µL/por pocillo. A continuación, las placas se incubaron durante 60 minutos a 37 ˚C. La configuración y los resultados del ELISA se resumen en la Tabla 2 siguiente.
Tabla 2
Resultados del ensayo ELISA
Adhesión:
Cliente Muestra testada Suero antiratón
500421
Ventana
Parámetros del ensayo
Paso
Reactivo Dilución en serie Solución tampón de dilución Concentración Volumen/pocillo Incubación
Revestimient o de Ag.
VMSI1357-98 0,15M PBS 2µg/ml 50µl ON@4C
Bloqueo
1% NFDM 0,15M PBS 10µg/ml 300 µl 2hr @37C
Dilución de la muestra
Véase debajo 5 x 1% NFDM en 0,15m PBS Partida @1,50 80 µl 2,5hr. @ 37C
Ac secundario
Gt-α-Mu-HRP ,15M PBS w/0,05% Tween 20 1 (10000) 50µl 1hr @ 37c
Diseño de la placa
Dilución de la muestra
1:50 1:250 1:1250 1:6250 1:31250 1:156250
1
2 3 4 5 6 7 8 9 10 11 12
Mu#1
A 1,8 9 0,0 1 1,8 1 0,0 0 1,8 2 0,0 0 1,60 0,00 1,06 0,0 0 0,5 6 0,0 0
Mu#2
B 1,7 6 0,0 1 1,8 7 0,0 0 1,7 3 0,0 0 1,25 0,00 0,60 0,0 0 0,2 5 0,0 0
Mu#3
C 1,7 0 0,0 1 1,8 3 0,0 0 1,8 7 0,0 0 1,50 0,00 0,95 0,0 1 0,3 7 0,0 0
Mu#4
D 1,7 5 0,0 1 1,7 3 0,0 0 1,8 3 0,0 0 1,49 0,01 0,98 0,0 0 0,4 2 0,0 0
Mu#5
E 1,6 2 0,0 1 1,5 8 0,0 0 1,7 2 0,0 0 1,35 0,00 ,074 0,0 0 0,3 3 0,0 0
Concentrad o premezcla (PbP)
F 0 ,06 0,0 1 0,0 1 0,0 0 0,0 0 0,0 1 0,00 0,00 0,00 0,0 0 0,0 0 0,0 0
x
x
x
x
x
x
Antígeno
VMSI-1357-98 Lot#C05081610 x = en blanco (sin antígeno)
Solución tampón de
0,15M PBS con 0,05% Tween 20 NFDM = leche en polvo desnatada
122
imagen119
imagen120
imagen121
imagen122
imagen123
imagen124
imagen125
imagen126
imagen127
imagen128
imagen129
imagen130
imagen131
5
10
15
20
25
30
35
1992 ; Pluckthun, Biotechnology 9:545, 1991 ; Huse et al., Science 246:1275, 1989 y Ward et al., Nature 341:544, 1989, incorporados todos al presente por referencia.
A menudo, las proteínas heterólogas funcionales de E. coli u otras bacterias se aíslan de los cuerpos de inclusión y exigen una solubilización utilizando potentes desnaturalizantes y su posterior repliegue. Durante el paso de solubilización, como se sabe en la técnica, debe estar presente un agente reductor para separar los enlaces disulfuro. Un ejemplo de solución tampón con un agente reductor es el siguiente: 0.1 M Tris pH 8, 6 M guanidina, 2 mM EDTA, 0,3 M DTE (ditioeritritol). La reoxidación de los enlaces disulfuro se puede producir en presencia de reactivos de tiol de bajo peso molecular en forma reducida y oxidada, tal como se describe en Saxena et al., Biochemistry 9: 5015-5021, 1970, incorporado al presente por referencia, y especialmente tal como se describe en Buchner et al., supra.
La renaturalización se realiza típicamente mediante dilución (por ejemplo, 100 veces) de la proteína desnaturalizada y reducida en solución tampón de replegado. Un ejemplo de solución tampón es 0,1 M Tris, pH 8.0, 0,5 M L-arginina, 8 mM glutatión oxidado (GSSG), y 2 mM EDTA.
Como modificación del protocolo de purificación de anticuerpos de doble cadena, las regiones de la cadena pesada y ligera se solubilizan y reducen por separado y, a continuación, se combinan en la solución de replegado. Un ejemplo de rendimiento se obtiene cuando estas dos proteínas se mezclan en un ratio molar de forma que no se supera un exceso molar de 5 veces de una proteína con respecto a la otra. Se recomienda añadir glutatión oxidado en exceso u otros compuestos oxidantes de bajo peso molecular a la solución de replegado una vez que se haya completado el intercambio-redox.
Además de los métodos recombinantes, los anticuerpos divulgados en el presente también se pueden producir, en su totalidad o en parte, utilizando la síntesis peptídica estándar. La síntesis en fase sólida de los polipéptidos de menos de unos 50 aminoácidos de longitud se puede realizar uniendo el aminoácido C-terminal de la secuencia con un soporte insoluble, seguido de la adición secuencial de los restantes aminoácidos de la secuencia. Las técnicas para la síntesis en fase sólida se describen en Barany & Merrifield, The Peptides: Analysis, Synthesis, Biology. Vol.
2: Special Methods in Peptide Synthesis, Part A. pp. 3-284 ; Merrifield et al., J. Am. Chem. Soc. 85:2149-2156, 1963 , y Stewart et al., Solid Phase Peptide Synthesis, 2ª ed., Pierce Chem. Co., Rockford, Ill., 1984 . Las proteínas de mayor longitud se pueden sintetizar mediante condensación de los términos amino y carboxilo de los fragmentos más cortos. Los métodos para formar enlaces peptídicos mediante activación de un extremo carboxi-terminal (como mediante el uso del reactivo de acoplamiento N,N'-diciclohexilcarbodiimida) son conocidos en la técnica.
XII. Antígenos
Algunos ejemplos de antígenos de interés incluyen los que se recogen a continuación:
Tabla 1
Ejemplos de antígenos de interés (antígenos diana)
Antígenos diana virales
Ejemplos de secuencias de antígenos diana de los antígenos diana SEC. ID. Nº:
BK
TLYKKMEQDVKVAHQ GNLPLMRKAYLRKCK TFSRMKYNICMGKCI 1 22 23
JC
SITEVECFL 2
Epstein-Barr (EBV)
QPRAPIRPI 3
citomegalovirus (CMV)
NLVPMVATV 4
HPV
YMLDLQPET(T) 5
Influenza A
GILGFVFTL 6
Antígenos diana del tumor y sus péptidos derivados
PRAME
LYVDSLFFL 7
136
WT1
RMFPNAPYL 8
Survivin
ELTLGEFLKL 9
AFP
GVALQTMKQ 10
ELF2M
ETVSEQSNV 11
proteinasa 3 y su péptido PR1
VLQELNVTV 12
elastasa de neutrófilos
VLQELNVTV 13
MAGE
EADPTGHSY 14
MART
AAGIGILTV 15
tirosinasa
RHRPLQEVYPEANAPIGHNRE 16
GP100
WNRQLYPEWTEAQRLD 17
NY-Eso-1
VLLKEFTVSG 18
Herceptin
KIFGSLAFL 19
antígeno carcinoembrionario (CEA)
HLFGYSWYK 20
PSA
FLTPKKLQCV 21
Antígeno diana fúngico
Blastomyces dermatitidis
CELDNSHEDYNWNLWFKWCSGHGR TGHGKHFYDCDWDPSHGDYSWYLW DPSHGDYSWYLWDYLCGNGHHPYD DYLCGNGHHPYDCELDNSHEDYSW DPYNCDWDPYHEKEKYDWDLWNKWCN KYDWDLWNKWCNKDPYNCDWDPYH 24 25 26 27 28 29
Tabla 2 Ejemplos de tumores y sus antígenos tumorales
Tumor
Antígenos diana asociados al tumor
Leucemia mielógena aguda
Tumor de Wilms 1 (WT1), preferiblemente antígeno de melanoma expresado (PRAME), PR1, proteinasa 3, elastasa catepsina G
Leucemia mielógena crónica
WT1, PRAME, PR1, proteinasa 3, elastasa, catepsina G
Síndrome mielodisplásico
WT1, PRAME, PR1, proteinasa 3, elastasa, catepsina G
Leucemia linfoblástica aguda
PRAME
Leucemia linfocítica crónica
Superviviente
Linfoma no Hodgkin
Superviviente
Mieloma múltiple
Nueva York esofágico 1 (NY-Eso-1)
Melanoma maligno
MAGE, MART, Tirosinasa, PRAME GP100
Cáncer de mama
WT1, herceptina
Cáncer de pulmón
WT1
Cáncer de próstata
Antígeno prostático específico (PSA)
137
imagen132

Claims (1)

  1. imagen1
ES12151520.9T 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso Active ES2491743T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85613306P 2006-11-01 2006-11-01
US856133P 2006-11-01

Publications (1)

Publication Number Publication Date
ES2491743T3 true ES2491743T3 (es) 2014-09-08

Family

ID=39430271

Family Applications (7)

Application Number Title Priority Date Filing Date
ES12151524.1T Active ES2493166T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES17192133T Active ES2761949T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES19178774T Active ES2905054T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES12151520.9T Active ES2491743T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES07867341T Active ES2570600T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES16151995.4T Active ES2663080T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES12150646.3T Active ES2465465T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES12151524.1T Active ES2493166T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES17192133T Active ES2761949T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES19178774T Active ES2905054T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES07867341T Active ES2570600T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES16151995.4T Active ES2663080T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
ES12150646.3T Active ES2465465T3 (es) 2006-11-01 2007-11-01 Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso

Country Status (8)

Country Link
US (5) US7695929B2 (es)
EP (7) EP2442107B1 (es)
JP (6) JP5576120B2 (es)
AU (1) AU2007322261B2 (es)
CA (5) CA3125026C (es)
DK (7) DK2078197T3 (es)
ES (7) ES2493166T3 (es)
WO (1) WO2008063378A2 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4868698B2 (ja) 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007050811A2 (en) 2005-10-27 2007-05-03 The President And Fellows Of Harvard College Methods and compositions for labeling nucleic acids
ES2493166T3 (es) * 2006-11-01 2014-09-11 Ventana Medical Systems, Inc. Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
CA2677792C (en) 2007-02-07 2015-04-14 Purdue Research Foundation Positron emission tomography imaging method
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2995925B1 (en) 2008-06-05 2021-12-15 Ventana Medical Systems, Inc. Composition for histochemical processing
JP5703219B2 (ja) * 2008-08-22 2015-04-15 ベンタナ・メデイカル・システムズ・インコーポレーテツド 単一サンプルにおける２以上のターゲット分子のクロモゲンを検出する方法
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
CN106519588B (zh) 2009-11-09 2019-08-20 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
USPP22463P3 (en) * 2010-02-16 2012-01-17 Menachem Bornstein Gypsophila plant named ‘Pearl Blossom’
WO2011106583A1 (en) 2010-02-26 2011-09-01 Ventana Medical Systems, Inc. Polytag probes
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
AU2011222501B2 (en) 2010-03-04 2014-05-01 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
WO2011133625A1 (en) 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
NO3056203T3 (es) 2010-04-21 2018-05-12
CA2792569C (en) 2010-04-27 2019-01-15 Ventana Medical Systems, Inc. Antibody-nanoparticle conjugates and methods for making and using such conjugates
US9291597B2 (en) 2010-07-02 2016-03-22 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
JP2013531801A (ja) * 2010-07-02 2013-08-08 ヴェンタナ メディカル システムズ， インク． 標的検出のためのハプテンコンジュゲート
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2606055B1 (en) 2010-08-16 2015-06-03 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
EP2944605B1 (en) 2010-10-18 2018-12-05 University of Washington through its Center for Commercialization Chromophoric polymer dots
CN107011333B (zh) * 2010-11-18 2021-03-19 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
EP2686438B1 (en) 2011-03-14 2018-04-18 Ventana Medical Systems, Inc. A method of analyzing chromosomal translocations and a system therefor
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
WO2013101902A2 (en) 2011-12-30 2013-07-04 University Of Washington, Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
CA2858993C (en) 2012-01-23 2018-12-04 Ventana Medical Systems, Inc. Polymer stabilization of chromogen solutions
WO2013116614A1 (en) 2012-02-03 2013-08-08 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
ES2678211T3 (es) 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Conjugados de señalización y procedimientos de uso
US9123538B2 (en) * 2012-04-26 2015-09-01 Regents Of The University Of Minnesota Silicon nanocrystal inks, films, and methods
CN102654500A (zh) * 2012-05-17 2012-09-05 重庆市科学技术研究院 一种检测喹噁啉-2-羧酸的检测试剂盒及其方法
ES2664952T3 (es) * 2012-08-21 2018-04-24 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
WO2014139979A1 (en) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Quantum dot in situ hybridization
ES2804300T3 (es) 2013-03-12 2021-02-05 Ventana Med Syst Inc Microscopía mejorada digitalmente para histología multiplexada
US9663814B2 (en) 2013-03-12 2017-05-30 Ventana Medical Systems, Inc. Proximity assay for in situ detection of targets
JP6587605B2 (ja) 2013-03-14 2019-10-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション ポリマードット組成物および関連方法
ES2729638T3 (es) * 2013-10-11 2019-11-05 Ventana Med Syst Inc Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral
EP3060917B1 (en) 2013-10-24 2019-05-15 Siemens Healthcare Diagnostics Inc. Assays for macromolecular analytes
SG11201605597VA (en) 2014-01-10 2016-08-30 Synthon Biopharmaceuticals Bv Duocarmycin adcs for use in treatment of endometrial cancer
AU2015205509B2 (en) 2014-01-10 2019-08-15 Byondis B.V. Duocarmycin ADCs showing improved in vivo antitumor activity
EP3111224B1 (en) 2014-02-24 2018-12-26 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
EP3110966A1 (en) 2014-02-24 2017-01-04 Ventana Medical Systems, Inc. Automated rna detection using labeled 2'-o-methyl rna oligonucleotide probes and signal amplification systems
CA2948420A1 (en) 2014-06-06 2015-12-10 Ventana Medical Systems, Inc. Significance of intratumoral her2 heterogeneity in breast cancer and uses therefore
EP3197919A1 (en) * 2014-09-22 2017-08-02 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins
CA2957783C (en) 2014-10-02 2023-02-28 Ventana Medical Systems, Inc. Polymers and conjugates comprising the same
DK3224621T3 (da) 2014-11-25 2019-08-12 Ventana Med Syst Inc Nærhedsanalyser under anvendelse af kemisk ligering og haptenoverførsel
JP6654634B2 (ja) 2014-12-03 2020-02-26 ベンタナ メディカル システムズ， インコーポレイテッド 不均一なバイオマーカー分布を定量的に分析するための方法、システム及び装置
WO2016127149A2 (en) 2015-02-06 2016-08-11 Cell Idx, Inc. Antigen-coupled immunoreagents
AU2016248882B2 (en) 2015-04-13 2020-04-30 Ventana Medical Systems, Inc. Thermochemical-based antibody inactivation methods and systems
WO2016166169A1 (en) 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
WO2016190236A1 (ja) * 2015-05-28 2016-12-01 コニカミノルタ株式会社 インサイチュハイブリダイゼイション用のプローブ試薬
CN105018072B (zh) * 2015-07-08 2017-02-01 山东理工大学 检测人血清白蛋白的荧光探针及其制备方法
CA2996798A1 (en) 2015-08-28 2017-03-09 Ventana Medical Systems, Inc. Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens
CA3004504A1 (en) 2015-11-06 2017-05-11 Ventana Medical Systems, Inc. Tissue homogenisation for representative diagnostics
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
WO2018002016A1 (en) 2016-06-28 2018-01-04 Ventana Medical Systems, Inc. Application of click chemistry for signal amplification in ihc and ish assays
EP3475701B1 (en) 2016-06-28 2023-02-22 Ventana Medical Systems, Inc. New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates
CN109716130B (zh) * 2016-07-18 2023-05-23 赛尔伊迪克斯公司 抗原偶联的杂交试剂
WO2018058029A1 (en) 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
CN110300806B (zh) * 2016-12-16 2024-03-19 艾瑞特姆有限责任公司 使用连接扩增的分子检测
CN110337588B (zh) 2016-12-19 2023-02-17 文塔纳医疗***公司 用于定量免疫组织化学的方法和***
CN110121364A (zh) 2016-12-19 2019-08-13 文塔纳医疗***公司 肽核酸缀合物
CA3049698A1 (en) * 2017-01-13 2018-07-19 National Research Council Of Canada Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines
CN117187346A (zh) 2017-03-31 2023-12-08 乌尔蒂维尤股份有限公司 Dna-抗原交换和扩增
US10768185B2 (en) * 2017-07-20 2020-09-08 Trustees Of Boston University Tenofovir detection assay
CN111491667A (zh) 2017-12-18 2020-08-04 文塔纳医疗***公司 肽核酸缀合物
WO2019194994A1 (en) * 2018-04-05 2019-10-10 Rarecyte, Inc. Analyte detection
US10330684B1 (en) 2018-04-05 2019-06-25 Rarecyte, Inc. Analyte detection
WO2019224153A1 (en) 2018-05-21 2019-11-28 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
WO2020058339A1 (en) * 2018-09-20 2020-03-26 Ventana Medical Systems, Inc. Coumarin-based crosslinking reagents
WO2020229578A1 (en) 2019-05-14 2020-11-19 Ventana Medical Systems, Inc. System including a biological sample treatment chamber
CN110330488A (zh) * 2019-06-20 2019-10-15 深圳市易瑞生物技术股份有限公司 一种吡罗昔康半抗原及其制备方法和应用
EP4077344A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Methods of sequencing by synthesis using a consecutive labeling scheme
US11814677B2 (en) * 2019-12-30 2023-11-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods and systems for sensitive and multiplexed analysis of biological samples using cleavable fluorescent streptavidin and anti-hapten antibodies
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021224293A1 (en) 2020-05-07 2021-11-11 Ventana Medical Systems, Inc. Histochemical systems and methods for evaluating egfr and egfr ligand expression in tumor samples
KR102506288B1 (ko) * 2020-09-07 2023-03-06 국립암센터 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도
CN112362863B (zh) * 2020-11-02 2024-02-13 上海市农业科学院 一种巯基功能化脂质体纳米材料及其制备方法和应用
EP4278181A1 (en) 2021-01-15 2023-11-22 Ventana Medical Systems, Inc. Storage stable caged haptens
EP4281779A1 (en) 2021-01-25 2023-11-29 Ventana Medical Systems, Inc. Stained biological specimens including one or more biomarkers labeled with one or more detectable moieties
EP4326736A1 (en) 2021-04-18 2024-02-28 Ventana Medical Systems, Inc. Morphological marker staining
WO2022240641A1 (en) * 2021-05-12 2022-11-17 The Scripps Research Institute High-throughput assay for identification of myc inhibitors
WO2023205669A2 (en) * 2022-04-19 2023-10-26 Purdue Research Foundation Dual and triple hapten conjugates, compositions, processes for making, and methods of treatment therewith
US20230383342A1 (en) * 2022-05-31 2023-11-30 Illumina Cambridge Limited Compositions and methods for nucleic acid sequencing
WO2024002924A2 (en) 2022-06-28 2024-01-04 F. Hoffmann-La Roche Ag Fluorescent dyes with large stokes shift

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892530A (en) 1974-09-23 1975-07-01 Hoffmann La Roche Colorimetric and fluorometric method
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4230683A (en) * 1978-08-09 1980-10-28 Abbott Laboratories Hapten conjugated antibody for antibody or antigen detection
US4223013A (en) * 1978-12-29 1980-09-16 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
US4495296A (en) 1979-05-21 1985-01-22 New York Blood Center, Inc. Labeled anti-hapten antibodies and their use as a universal reagent for solid phase radio- and/or enzyme-immunoassays
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4425427A (en) 1980-03-13 1984-01-10 Vitafin N.V. Simultaneous, kinetic, spectrophotometric analysis of blood serum for multiple components
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4490473A (en) * 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US4879224A (en) 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2039025T3 (es) 1987-11-16 1993-08-16 Janssen Pharmaceutica N.V. Un agregado para determinar sustancias combinables.
DE3811692A1 (de) * 1988-04-07 1989-10-19 Idt Ag Fuer In Vivo Diagnostik Diagnostikverfahren und mittel zur diagnose und behandlung immunologischer erkrankungen
CA1308022C (en) * 1988-08-11 1992-09-29 Eleftherios P. Diamandis Multiple fluorescence labelling with europium chelators
DE3836656A1 (de) 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5225325A (en) 1990-03-02 1993-07-06 Ventana Medical Systems, Inc. Immunohistochemical staining method and reagents therefor
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
DE69232801T2 (de) * 1991-03-20 2003-08-14 Marconi Optical Components Ltd., London Abtrennungsverfahren
WO1993020094A1 (en) * 1992-03-27 1993-10-14 Abbott Laboratories Haptens, tracers, immunogens and antibodies for quinoline
US6100099A (en) * 1994-09-06 2000-08-08 Abbott Laboratories Test strip having a diagonal array of capture spots
US5403747A (en) 1992-04-01 1995-04-04 Thomas Jefferson University Protein assay using microwave energy
US5350686A (en) 1992-04-16 1994-09-27 Pioneer Hi-Bred International, Inc. Microwave acceleration of enzyme-catalyzed modification of macromolecules
US5834202A (en) 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5393891A (en) 1993-06-08 1995-02-28 The Du Pont Merck Pharmaceutical Company Immunoassay reagents and methods for detecting brequinar and analogs
US5679582A (en) 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5661040A (en) 1993-07-13 1997-08-26 Abbott Laboratories Fluorescent polymer labeled conjugates and intermediates
CA2166782A1 (en) * 1993-07-20 1995-02-02 James R. Fino Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives
US5731171A (en) 1993-07-23 1998-03-24 Arch Development Corp. Sequence independent amplification of DNA
US5643761A (en) 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
US5487975A (en) 1993-11-15 1996-01-30 Ventana Medical Systems, Inc. Biotin/avidin formulation
DE4407538C1 (de) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Bindungsreagens für Zell-Oberflächenprotein und Effektorzelle
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
GB9420355D0 (en) 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US6057099A (en) 1994-12-02 2000-05-02 Intelligene Ltd. Detection of nucleic acid sequences
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5648245A (en) 1995-05-09 1997-07-15 Carnegie Institution Of Washington Method for constructing an oligonucleotide concatamer library by rolling circle replication
US5684142A (en) 1995-06-07 1997-11-04 Oncor, Inc. Modified nucleotides for nucleic acid labeling
US5883081A (en) 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6767702B2 (en) 1996-07-29 2004-07-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
JPH10104230A (ja) * 1996-09-30 1998-04-24 Aisin Seiki Co Ltd 核酸等の検出方法，並びに標識物質及び検出物質
EP0951566B1 (en) 1996-10-04 2002-12-18 Universität Heidelberg A method of purifying dna
US5952890A (en) 1997-02-05 1999-09-14 Fox Enterprises, Inc. Crystal oscillator programmable with frequency-defining parameters
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING NON-METHYLATED CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE-ASSOCIATED ILLNESSES
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
JPH1151935A (ja) * 1997-08-06 1999-02-26 Aisin Seiki Co Ltd 複数種類のターゲット分子の同時検出方法
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
JPH11240879A (ja) * 1997-12-22 1999-09-07 Nissan Chem Ind Ltd ピラゾールスルホニルウレアのポリクローナル抗体及び検出方法
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6855559B1 (en) 1998-09-03 2005-02-15 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6296809B1 (en) 1998-02-27 2001-10-02 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6235480B1 (en) 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6855552B2 (en) 1998-09-03 2005-02-15 Ventana Medical Systems Automated immunohistochemical and in situ hybridization assay formulations
US7550298B2 (en) 1998-09-03 2009-06-23 Ventana Medical Systems, Inc. Automated immunohistochemical and in situ hybridization assay formulations
JP2000095769A (ja) * 1998-09-22 2000-04-04 Kankyo Meneki Gijutsu Kenkyusho:Kk プロベナゾールのハプテン化合物、抗体及び測定方法
DE69938353T2 (de) 1998-09-24 2009-03-05 Indiana University Research and Technology Corp., Indianapolis Wasserlösliche lumineszente quantum-dots sowie deren biokonjugate
US6414133B1 (en) 1998-10-13 2002-07-02 Ventana Medical Systems, Inc. Multiple fusion probes
US7569344B2 (en) 1998-10-26 2009-08-04 Ventana Medical Systems, Inc. Detection of human papilloma virus in papanicolaou (Pap) smears
US6432320B1 (en) 1998-11-02 2002-08-13 Patrick Bonsignore Refrigerant and heat transfer fluid additive
US6699973B1 (en) 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
WO2000041524A2 (en) 1999-01-11 2000-07-20 President And Fellows Of Harvard College Isothermal amplification of dna
AU3498200A (en) 1999-02-19 2000-09-04 Michigan State University An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US6544798B1 (en) 1999-02-26 2003-04-08 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US6673214B1 (en) 1999-04-09 2004-01-06 Rocky Mountain Biosystems, Inc. Energy enhanced reaction catalysis and uses thereof
DE50015293D1 (de) 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
DE60042738D1 (de) * 1999-05-07 2009-09-24 Life Technologies Corp Verfahren zum nachweis von analyten mit hilfe von halbleiternanokrystallen
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
DE19933701A1 (de) 1999-07-19 2001-01-25 Wilex Biotechnology Gmbh Zyklische peptidomimetische Urokinaserezeptorantagonisten
JP2001089484A (ja) * 1999-09-22 2001-04-03 Kankyo Meneki Gijutsu Kenkyusho:Kk トリシクラゾールのハプテン化合物、抗体及び測定方法
EP1218547A4 (en) * 1999-10-15 2005-04-20 Ventana Med Syst Inc METHOD FOR DETECTING UNIQUE GENE IN SITU COPIES
US20060275784A1 (en) 1999-10-26 2006-12-07 Ventana Medical Systems, Inc. Detection of Human Papilloma Virus in Papanicolaou (Pap) Smears
MXPA02006778A (es) 2000-01-12 2004-04-05 Ventana Inc Metodo para determinar la respuesta a una terapia de cancer.
JP4951184B2 (ja) 2000-03-20 2012-06-13 マサチューセッツ インスティテュート オブ テクノロジー 無機粒子結合体
JP4317913B2 (ja) 2000-04-14 2009-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド Ａｋｔタンパク質発現の定量方法
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
NZ522406A (en) 2000-05-16 2006-05-26 Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
US6828097B1 (en) 2000-05-16 2004-12-07 The Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
US7763421B2 (en) 2000-06-05 2010-07-27 Ventana Medical Systems, Inc. Methods for producing nucleic acid hybridization probes that amplify hybridization signal by promoting network formation
US6323009B1 (en) 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US6447692B1 (en) 2000-08-04 2002-09-10 Hrl Laboratories, Llc Nanometer sized phase change materials for enhanced heat transfer fluid performance
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US20040209303A1 (en) 2000-10-03 2004-10-21 Martin Mark T. Methods and compositions for directed microwave chemistry
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6576291B2 (en) 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
KR100991573B1 (ko) 2000-12-11 2010-11-04 프레지던트 앤드 펠로우즈 오브 하버드 칼리지 나노센서
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US20030022166A1 (en) 2001-01-19 2003-01-30 Colin Collins Repeat-free probes for molecular cytogenetics
US6656685B2 (en) 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
WO2003004944A2 (en) 2001-01-30 2003-01-16 Materials And Electrochemical Research (Mer) Corporation Nano carbon materials for enhancing thermal transfer in fluids
DE10105912A1 (de) 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
ES2400448T3 (es) 2001-04-30 2013-04-10 Ventana Medical Systems, Inc. Reactivos y métodos para la hibridación automatizada in situ o para microarray
US20030003537A1 (en) 2001-04-30 2003-01-02 Ventana Medical Systems, Inc. Method and composition of matter for enhancing staining of microorganisms
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
AU2002310497A1 (en) 2001-06-20 2003-01-08 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
CN1257408C (zh) * 2001-07-02 2006-05-24 北极医疗诊断有限公司 双光子吸收二吡咯亚甲基二氟化硼染料及其应用
EP1409240B1 (en) 2001-07-20 2012-05-09 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
US20030066998A1 (en) 2001-08-02 2003-04-10 Lee Howard Wing Hoon Quantum dots of Group IV semiconductor materials
AU2002334874B2 (en) * 2001-10-09 2007-09-06 3-Dimensional Pharmaceuticals, Inc. Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
US6617137B2 (en) 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US6977148B2 (en) 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
AU2002365894A1 (en) 2001-11-30 2003-06-17 Children's Hospital Medical Center Antibodies to magmas and uses thereof
US20050019901A1 (en) 2002-01-31 2005-01-27 Evgenia Matveeva Methods for synthesis of bio-active nanoparticles and nanocapsules for use in optical bio-disc assays and disc assembly including same
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US7476442B2 (en) 2002-07-17 2009-01-13 Massachusetts Institute Of Technology Nanoparticle chains and preparation thereof
JP2006506447A (ja) * 2002-10-25 2006-02-23 センス プロテオミック リミテッド Ｂｌｅ遺伝子によってコードされているタンパク質、及びブレオマイシン・ファミリー由来抗生物質の新規使用方法
US7200252B2 (en) 2002-10-28 2007-04-03 Ventana Medical Systems, Inc. Color space transformations for use in identifying objects of interest in biological specimens
US7233817B2 (en) 2002-11-01 2007-06-19 Brian Yen Apparatus and method for pattern delivery of radiation and biological characteristic analysis
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
GB0227738D0 (en) 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7056471B1 (en) 2002-12-16 2006-06-06 Agency For Science Technology & Research Ternary and quarternary nanocrystals, processes for their production and uses thereof
US20040229300A1 (en) 2003-04-22 2004-11-18 Frederickson Christopher J. Zinc-based screening test and kit for early diagnosis of prostate cancer
US6944333B2 (en) 2003-04-30 2005-09-13 Ventana Medical Systems, Inc. Color image compression via spectral decorrelation and elimination of spatial redundancy
WO2005001889A2 (en) 2003-05-07 2005-01-06 Indiana University Research & Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
JP4637847B2 (ja) 2003-05-19 2011-02-23 ベンタナ・メデイカル・システムズ・インコーポレーテツド 電気泳動によるそのインサイチューでの組織染色
US20050181394A1 (en) 2003-06-20 2005-08-18 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
DK1636586T3 (da) 2003-06-24 2009-11-23 Ventana Med Syst Inc Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser
KR100657891B1 (ko) 2003-07-19 2006-12-14 삼성전자주식회사 반도체 나노결정 및 그 제조방법
US20050048498A1 (en) 2003-08-29 2005-03-03 Applera Corporation Compositions, methods, and kits for assembling probes
KR100571817B1 (ko) 2003-09-19 2006-04-17 삼성전자주식회사 태그 서열에 혼성화하는 검출 프로브를 이용하는 표적핵산의 검출방법
JP2007506429A (ja) 2003-09-23 2007-03-22 アトム・サイエンシズ・インコーポレーテッド ポリマー核酸のハイブリダイゼーションプローブ
US7638606B2 (en) 2003-11-07 2009-12-29 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2005064018A2 (en) * 2003-12-22 2005-07-14 Ventana Medical Systems, Inc. Microwave mediated synthesis of nucleic acid probes
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US7104313B2 (en) 2003-12-31 2006-09-12 Intel Corporation Apparatus for using fluid laden with nanoparticles for application in electronic cooling
US7244665B2 (en) 2004-04-29 2007-07-17 Micron Technology, Inc. Wafer edge ring structures and methods of formation
EP1753876A2 (en) * 2004-05-04 2007-02-21 Ventana Medical Systems, Inc. Internal control in situ hybridization
US20060110744A1 (en) 2004-11-23 2006-05-25 Sampas Nicolas M Probe design methods and microarrays for comparative genomic hybridization and location analysis
US7947839B2 (en) * 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20060160116A1 (en) 2004-12-16 2006-07-20 The Regents Of The University Of California Repetitive sequence-free DNA libraries
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
US7615800B2 (en) 2005-09-14 2009-11-10 Eastman Kodak Company Quantum dot light emitting layer
EP1951316B1 (en) * 2005-11-23 2015-08-19 Ventana Medical Systems, Inc. Molecular conjugate
ATE456053T1 (de) 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs
CA2661713C (en) 2006-09-01 2016-08-02 Ventana Medical Systems, Inc. Method for producing nucleic acid probes
ES2493166T3 (es) * 2006-11-01 2014-09-11 Ventana Medical Systems, Inc. Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
US7682789B2 (en) 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
DK2167963T3 (da) * 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
WO2010104899A1 (en) * 2009-03-12 2010-09-16 Glaxosmithkline Llc Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors

Also Published As

Publication number Publication date
CA3069091A1 (en) 2008-05-29
JP5576120B2 (ja) 2014-08-20
JP2018040813A (ja) 2018-03-15
EP2442107A3 (en) 2012-11-14
CA2995467A1 (en) 2008-05-29
JP2013231044A (ja) 2013-11-14
EP2444807A2 (en) 2012-04-25
EP3564674B1 (en) 2021-08-25
EP3029461B1 (en) 2017-12-20
EP3276349A1 (en) 2018-01-31
EP2442107A2 (en) 2012-04-18
CA3125026C (en) 2023-04-04
CA2858359C (en) 2018-04-03
EP3029461A1 (en) 2016-06-08
JP2016136150A (ja) 2016-07-28
JP5973524B2 (ja) 2016-08-23
EP2444806B1 (en) 2014-05-28
JP2020126057A (ja) 2020-08-20
AU2007322261A1 (en) 2008-05-29
ES2493166T3 (es) 2014-09-11
JP5722952B2 (ja) 2015-05-27
CA2666234C (en) 2014-10-14
CA2858359A1 (en) 2008-05-29
ES2761949T3 (es) 2020-05-21
US8846320B2 (en) 2014-09-30
EP2078197A2 (en) 2009-07-15
EP2078197A4 (en) 2010-03-24
JP6691092B2 (ja) 2020-04-28
JP6259477B2 (ja) 2018-01-10
US11092594B2 (en) 2021-08-17
AU2007322261B2 (en) 2014-01-23
US20100297725A1 (en) 2010-11-25
US9719986B2 (en) 2017-08-01
DK3029461T3 (en) 2018-02-05
DK2444806T3 (da) 2014-07-21
WO2008063378A9 (en) 2008-07-31
CA2666234A1 (en) 2008-05-29
EP2444807A3 (en) 2013-02-27
CA3125026A1 (en) 2008-05-29
US20180120306A1 (en) 2018-05-03
WO2008063378A3 (en) 2008-12-04
US20100184087A1 (en) 2010-07-22
WO2008063378A2 (en) 2008-05-29
ES2905054T3 (es) 2022-04-06
CA2995467C (en) 2020-03-10
EP2444807B1 (en) 2014-06-11
EP2442107B1 (en) 2014-03-12
ES2570600T3 (es) 2016-05-19
EP2444806A3 (en) 2013-02-27
JP2015072275A (ja) 2015-04-16
ES2465465T3 (es) 2014-06-05
US20080268462A1 (en) 2008-10-30
CA3069091C (en) 2021-09-14
DK3564674T3 (da) 2021-10-18
JP2010508532A (ja) 2010-03-18
EP3276349B1 (en) 2019-08-07
US8618265B2 (en) 2013-12-31
JP7000489B2 (ja) 2022-01-19
EP2444806A2 (en) 2012-04-25
ES2663080T3 (es) 2018-04-11
DK3276349T3 (da) 2019-10-28
DK2444807T3 (da) 2014-08-11
US7695929B2 (en) 2010-04-13
DK2442107T3 (da) 2014-05-19
EP2078197B1 (en) 2016-03-23
US20140323336A1 (en) 2014-10-30
DK2078197T3 (en) 2016-05-23
EP3564674A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
ES2491743T3 (es) Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
Fernández-Moreira et al. Bioconjugated lanthanide luminescent helicates as multilabels for lab-on-a-chip detection of cancer biomarkers
US6867007B2 (en) Binary or polynary targeting and uses thereof
US8524457B2 (en) Method for the selection of specific affinity binders by homogeneous noncompetitive assay
CN106442982B (zh) 一种禽白血病病毒j亚群特异抗原多肽及其应用
CN105785016A (zh) 基于pg磁微粒的双标记时间分辨荧光免疫分析试剂盒
JP2007529747A (ja) センサ構造物及び検出方法
ES2636483T3 (es) Métodos y sistemas para la amplificación de señal de bioensayos
Shiu et al. Phosphorescent proteins for bio-imaging and site selective bio-conjugation of peptides and proteins with luminescent cyclometalated iridium (iii) complexes
AR064186A1 (es) Inmunoensayos de alta sensibilidad y kits para la determinacion de peptidos y proteinas de interes biologico
JP2013511546A5 (es)
Hoshino et al. Simultaneous Multicolor Detection System of the Single‐Molecular Microbial Antigen with Total Internal Reflection Fluorescence Microscopy
CN106255880A (zh) 用于测定样品中可溶性抗体的存在的基于蛋白l的生物测定方法及其试剂盒
WO1988008982A1 (en) Method for immunoassay utilizing liposome and kit therefor
RU2638787C1 (ru) Способ получения аналитической тест-системы на основе суспензионных микрочипов для детекции маркеров заболеваний
Sutoh et al. Improved method for mapping the binding site of an actin-binding protein in the actin sequence. Use of a site-directed antibody against the N-terminal region of actin as a probe of its N-terminus
ES2901720T3 (es) Preparación de partículas portadoras insolubles visibles, coloreadas con un colorante marcador fluorescente, y método de inmunoensayo mediante el uso de dichas partículas
JP4124961B2 (ja) サンプル中の抗体を検出する方法
Eliseeva et al. Increasing the efficiency of lanthanide luminescent bioprobes: bioconjugated silica nanoparticles as markers for cancerous cells
CN108603877A (zh) 使用多基质的分析物检测
CN106596692B (zh) 一种弯曲毛细管电泳检测抗体多肽相互作用的方法
CN114478716B (zh) 一种多肽组合及其在新型冠状病毒抗体检测中的应用
JP2010210444A (ja) 多抗原同時検出用ナノ粒子
Okochi et al. A molecular peptide beacon for IgG detection
JP2010122002A (ja) 抗体の検出方法及び該方法に用いられる試薬キット